CR9415A - Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib - Google Patents

Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib

Info

Publication number
CR9415A
CR9415A CR9415A CR9415A CR9415A CR 9415 A CR9415 A CR 9415A CR 9415 A CR9415 A CR 9415A CR 9415 A CR9415 A CR 9415A CR 9415 A CR9415 A CR 9415A
Authority
CR
Costa Rica
Prior art keywords
egfr
inhibitor
ephermal
growth factor
resistant patients
Prior art date
Application number
CR9415A
Other languages
English (en)
Inventor
Charles M Zacharchuk
Susan E Quinn
Patricia Martins
Lee Greenberger
Ante Bill Lundberg
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9415A publication Critical patent/CR9415A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invencion describe un metodo para tratar o inhibir el cancer en un humano que tiene al menos uno de un E746-A750 eliminacion de exon 19 y/o una mutacion de punto exon 21 que comprende administrar a dicho humano gefitinib y/o iressa solo o en combinacion con otros agentes citotoxicos o agentes quimioterapeuticos y una cantidad efectiva del inhibidor de cinasa EGFR.
CR9415A 2005-04-14 2007-10-04 Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib CR9415A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67128705P 2005-04-14 2005-04-14

Publications (1)

Publication Number Publication Date
CR9415A true CR9415A (es) 2008-01-21

Family

ID=36791648

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9415A CR9415A (es) 2005-04-14 2007-10-04 Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib

Country Status (19)

Country Link
US (1) US20060235046A1 (es)
EP (1) EP1871371A2 (es)
JP (1) JP2008536847A (es)
KR (1) KR20080002826A (es)
CN (1) CN101160129A (es)
AR (1) AR053357A1 (es)
AU (1) AU2006236940A1 (es)
BR (1) BRPI0610574A2 (es)
CA (1) CA2646257A1 (es)
CR (1) CR9415A (es)
GT (1) GT200600146A (es)
IL (1) IL186302A0 (es)
MX (1) MX2007012662A (es)
NO (1) NO20074722L (es)
PE (1) PE20061396A1 (es)
RU (1) RU2007134908A (es)
TW (1) TW200718421A (es)
WO (1) WO2006113151A2 (es)
ZA (1) ZA200708755B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) * 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
JP2012501654A (ja) * 2008-09-05 2012-01-26 アビラ セラピューティクス， インコーポレイテッド 不可逆的インヒビターの設計のためのアルゴリズム
WO2010086382A1 (en) * 2009-01-30 2010-08-05 Pronota N.V. Target for treatment of acute heart failure
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
CN102713618B (zh) * 2009-09-16 2015-07-15 新基阿维罗米克斯研究公司 蛋白激酶复合物和抑制剂
WO2011082285A1 (en) 2009-12-30 2011-07-07 Avila Therapeutics, Inc. Ligand-directed covalent modification of protein
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US9364469B1 (en) * 2015-08-26 2016-06-14 Macau University Of Science And Technology Identification of a new AMPK activator for treatment of lung cancer
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
KR20060054412A (ko) * 2003-08-01 2006-05-22 와이어쓰 홀딩스 코포레이션 암 치료 및 억제용 표피 성장인자 수용체 키나제 억제제와세포독성제의 배합물 용도
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP2439284B1 (en) * 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
NZ556673A (en) * 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor

Also Published As

Publication number Publication date
AU2006236940A1 (en) 2006-10-26
TW200718421A (en) 2007-05-16
AR053357A1 (es) 2007-05-02
WO2006113151A2 (en) 2006-10-26
MX2007012662A (es) 2008-04-04
CN101160129A (zh) 2008-04-09
PE20061396A1 (es) 2007-01-12
IL186302A0 (en) 2008-08-07
JP2008536847A (ja) 2008-09-11
CA2646257A1 (en) 2006-10-26
WO2006113151A3 (en) 2007-01-11
GT200600146A (es) 2006-11-07
US20060235046A1 (en) 2006-10-19
ZA200708755B (en) 2008-10-29
KR20080002826A (ko) 2008-01-04
EP1871371A2 (en) 2008-01-02
RU2007134908A (ru) 2009-05-20
BRPI0610574A2 (pt) 2010-07-06
NO20074722L (no) 2007-11-12

Similar Documents

Publication Publication Date Title
ECSP066341A (es) Uso de una combinación de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico y agentes citotóxicos para el tratamiento e inhibición del cáncer
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
ECSP067068A (es) DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA PARA LA INHIBICIÓN DE b-SECRETASA
AR048819A1 (es) Metodos sinergicos y composiciones para el tratamiento del cancer
ECSP067080A (es) DIFENILIMIDAZOPIRIMIDINA Y AMINAS IMIDAZOL COMO INHIBIDORES DE ß-SECRETASA
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
NO20074722L (no) Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
CL2012000755A1 (es) Compuestos especificos 2-(3-amino-1-(2,4-difluorofenil)-1h-1,2,4-triazol-5-il)-n-metil-4,5-dihidrobenzeno(b) tieno(2,3-d)oxepina-8-carboxamida, inhibidor de la ctividad de la quinasa p13; composicon farmaceutica que lo comprende; kit farmaceutico que incluye a la composicion, y su uso para el tratamiento o profilaxis del cancer.
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
WO2009009173A3 (en) Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
IL184617A (en) Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody
PL1689724T3 (pl) Związki chinazolinonowe jako leki przeciwnowotworowe
ECSP088619A (es) Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
ECSP056114A (es) Combinaciones antineoplásicas
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
ZA200801332B (en) Pentacyclic kinase inhibitors
MXPA05011858A (es) Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.
IL162862A0 (en) Short-acting sedative hypnotic agents for anesthesia and sedation
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)